A detailed history of Blume Capital Management, Inc. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Blume Capital Management, Inc. holds 1,250 shares of ITCI stock, worth $106,837. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,250
Previous 1,250 -0.0%
Holding current value
$106,837
Previous $85,000 7.06%
% of portfolio
0.02%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 10, 2021

BUY
$29.3 - $44.5 $7,325 - $11,125
250 Added 25.0%
1,250 $51,000
Q3 2017

Nov 13, 2017

BUY
$10.77 - $22.1 $10,770 - $22,100
1,000
1,000 $16,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.07B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Blume Capital Management, Inc. Portfolio

Follow Blume Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blume Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blume Capital Management, Inc. with notifications on news.